Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q2-2022 Ophthalmology Update

Skip to the end of the Expertise Menu

Q2-2022 Ophthalmology Update

The ophthalmology space continues to be one of the most active specialties within physician services as macroeconomic concerns have, so far, done very little to slow the pace of dealmaking within the sector. In addition to a slew of strategic add on transactions, the quarter also saw a new private equity firm invest into the space by way of Vision Innovation Partners (VIP), a platform formerly backed by Centre Partners. With over 60% of platforms at least four years into their investment, Provident expects secondary buyouts, similar to the VIP transaction, to play a large role in consolidating a very fragmented space. While multiple PE-backed platforms have launched marketing processes of their own, Provident is tracking macroeconomic and inflationary conditions which may ultimately impact the timing on some of those processes.

To print and download the full Ophthalmology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2022/07/Q2-2022-Ophthalmology-Newsletter.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]


Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.